PMID- 35881421
OWN - NLM
STAT- MEDLINE
DCOM- 20220915
LR  - 20231002
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Linking)
VI  - 27
IP  - 5
DP  - 2022 Oct 1
TI  - DSA in solid organ transplantation: is it a matter of specificity, amount, or 
      functional characteristics?
PG  - 392-398
LID - 10.1097/MOT.0000000000001006 [doi]
AB  - PURPOSE OF REVIEW: The present review describes the clinical relevance of human 
      leukocyte antigen (HLA) donor-specific antibodies (HLA-DSAs) as biomarkers of 
      alloimmunity and summarizes recent improvements in their characterization that 
      provide insights into immune risk assessment, precision diagnosis, and 
      prognostication in transplantation. RECENT FINDINGS: Recent studies have 
      addressed the clinical utility of HLA-DSAs as biomarkers for immune risk 
      assessment in pretransplant and peritransplant, diagnosis and treatment 
      evaluation of antibody-mediated rejection, immune monitoring posttransplant, and 
      risk stratification. SUMMARY: HLA-DSAs have proved to be the most advanced immune 
      biomarkers in solid organ transplantation in terms of analytical validity, 
      clinical validity and clinical utility. Recent studies are integrating multiple 
      HLA-DSA characteristics including antibody specificity, HLA class, quantity, 
      immunoglobulin G subclass, and complement-binding capacity to improve risk 
      assessment peritransplant, diagnosis and treatment evaluation of 
      antibody-mediated rejection, immune monitoring posttransplant, and transplant 
      prognosis evaluation. In addition, integration of HLA-DSAs to clinical, 
      functional and histological transplant parameters has further consolidated the 
      utility of HLA-DSAs as robust biomarkers and allows to build new tools for 
      monitoring, precision diagnosis, and risk stratification for individual patients. 
      However, prospective and randomized-controlled studies addressing the clinical 
      benefit and cost-effectiveness of HLA-DSA-based monitoring and patient management 
      strategies are required to demonstrate that the use of HLA-DSAs as biomarkers can 
      improve current clinical practice and transplant outcomes.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Louis, Kevin
AU  - Louis K
AD  - Kidney Transplant Department, Saint Louis Hospital, Assistance Publique-Hopitaux 
      de Paris.
AD  - Human Immunology and Immunopathology, Universite de Paris.
FAU - Lefaucheur, Carmen
AU  - Lefaucheur C
AD  - Kidney Transplant Department, Saint Louis Hospital, Assistance Publique-Hopitaux 
      de Paris.
AD  - Paris Translational Research Center for Organ Transplantation, Institut national 
      de la sante et de la recherche medicale UMR-S970, Universite de Paris, Paris, 
      France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220722
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
RN  - 0 (Antibodies)
RN  - 0 (Biomarkers)
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Antibodies
MH  - Biomarkers
MH  - Graft Rejection/diagnosis/prevention & control
MH  - Graft Survival
MH  - HLA Antigens
MH  - Humans
MH  - Isoantibodies
MH  - *Kidney Transplantation
MH  - *Organ Transplantation/adverse effects
MH  - Prospective Studies
MH  - Tissue Donors
EDAT- 2022/07/27 06:00
MHDA- 2022/09/16 06:00
CRDT- 2022/07/26 11:52
PHST- 2022/07/27 06:00 [pubmed]
PHST- 2022/09/16 06:00 [medline]
PHST- 2022/07/26 11:52 [entrez]
AID - 00075200-202210000-00006 [pii]
AID - 10.1097/MOT.0000000000001006 [doi]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2022 Oct 1;27(5):392-398. doi: 
      10.1097/MOT.0000000000001006. Epub 2022 Jul 22.